Abidi, M.H., Tageja, N., Ayash, L., Abrams, J., Ratanatharathorn, V., Al-Kadhimi, Z., … Uberti, J. (2011). Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: A phase II trial. Supportive Care in Cancer, 20, 2363–2369.doi: 10.1007/s00520-011-1341-3
To investigate the efficacy and safety of aprepitant as a three-day antiemetic regimen for patients receiving single-dose cyclophosphamide 4 g/m2 for peripheral blood stem cell mobilization
Baseline nausea and vomiting was recorded pretreatment, then patients received granisetron, dexamethasone, and 125 mg oral aprepitant followed by cyclophosphamide on day 1. Patients received 80 mg oral aprepitant on days 2 and 3. No rescue medication use was allowed. Nausea, vomiting, and use of antiemetics were monitored daily for 5 days, then 7 and 30 days after initiation of chemotherapy. Toxicity was monitored using the National Cancer Institute's (NCI's) Common Toxicity Criteria (CTC), version 3.0.
This was a single site study conducted in Detroit, MI. The setting type was not specified.
This was a phase 2, clinical trial.
Aprepitant provides protection of acute and delayed vomiting following cyclophosphamide administration during stem cell mobilization. Aprepitant does not adequately control nausea following cyclophosphamide administration during stem cell mobilization.
Patients receiving cyclophosphamide for stem cell mobilization can experience nausea and vomiting requiring interventions. The addition of aprepitant to an antiemetic regimen of 5-HT3 antagonist plus dexamethasone improved control of acute and delayed vomiting following cyclophosphamide administration during stem cell mobilization. Aprepitant was associated with few toxicities.